CN106471125B - 包括白蛋白结合部分的腺病毒 - Google Patents

包括白蛋白结合部分的腺病毒 Download PDF

Info

Publication number
CN106471125B
CN106471125B CN201580023575.8A CN201580023575A CN106471125B CN 106471125 B CN106471125 B CN 106471125B CN 201580023575 A CN201580023575 A CN 201580023575A CN 106471125 B CN106471125 B CN 106471125B
Authority
CN
China
Prior art keywords
adenovirus
genome
protein
gene
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580023575.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106471125A (zh
Inventor
莱蒙·阿莱马尼·伯纳斯特里
路易斯·阿方索·罗哈斯·埃斯波西托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut d'Investigació Biomédica de Bellvitge
Institut Català d'Oncologia
Original Assignee
Institut d'Investigació Biomédica de Bellvitge
Institut Català d'Oncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia filed Critical Institut d'Investigació Biomédica de Bellvitge
Publication of CN106471125A publication Critical patent/CN106471125A/zh
Application granted granted Critical
Publication of CN106471125B publication Critical patent/CN106471125B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580023575.8A 2014-04-30 2015-04-30 包括白蛋白结合部分的腺病毒 Active CN106471125B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382162.7 2014-04-30
EP14382162.7A EP2940128A1 (en) 2014-04-30 2014-04-30 Adenovirus comprising an albumin-binding moiety
PCT/EP2015/059593 WO2015166082A1 (en) 2014-04-30 2015-04-30 Adenovirus comprising an albumin-binding moiety

Publications (2)

Publication Number Publication Date
CN106471125A CN106471125A (zh) 2017-03-01
CN106471125B true CN106471125B (zh) 2021-04-06

Family

ID=50774820

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580023575.8A Active CN106471125B (zh) 2014-04-30 2015-04-30 包括白蛋白结合部分的腺病毒

Country Status (12)

Country Link
US (3) US10604549B2 (enExample)
EP (2) EP2940128A1 (enExample)
JP (1) JP6639412B2 (enExample)
KR (1) KR102628234B1 (enExample)
CN (1) CN106471125B (enExample)
AU (1) AU2015254535B2 (enExample)
BR (1) BR112016025297B1 (enExample)
CA (1) CA2946650C (enExample)
IL (1) IL248590B (enExample)
MX (1) MX381286B (enExample)
RU (1) RU2711371C2 (enExample)
WO (1) WO2015166082A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
US20200330581A1 (en) * 2017-10-09 2020-10-22 Keith Black Oncolytic cancer immunotherapies and methods of use
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
US20220133823A1 (en) * 2018-09-10 2022-05-05 Genesail Biotech (Shanghai) Co. Ltd. A modified oncolytic virus, composition and use thereof
IL283165B2 (en) * 2018-11-21 2024-12-01 Mayo Found Medical Education & Res Adenoviruses and methods for using adenoviruses
MX2021010577A (es) 2019-04-29 2021-10-13 Mayo Found Medical Education & Res Compuestos de union a pd-l1 multivalentes para tratar cancer.
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
CN116271066B (zh) * 2021-12-13 2026-02-06 康希诺生物股份公司 一种重组腺病毒载体疫苗吸入给药递送系统
CN114159556B (zh) * 2021-12-14 2023-06-16 中国人民解放军军事科学院军事医学研究院 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体
WO2023120762A1 (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
JP7882551B2 (ja) * 2021-12-21 2026-06-30 キュリジン カンパニー，リミテッド 免疫回避性抗腫瘍アデノウイルス
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
CN115624524B (zh) * 2022-10-25 2023-10-27 中国医科大学附属第一医院 Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用
WO2026042009A1 (en) * 2024-08-19 2026-02-26 Theriva Biologics S.L. Modified adenovirus by hexon hypervariable region 7 (hvr7) gene insertion

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439055A (zh) * 2000-05-26 2003-08-27 住友制药株式会社 具有副作用降低的特性的新型重组腺病毒载体
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
CN101781636A (zh) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
CN101802013A (zh) * 2007-07-16 2010-08-11 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
CN102548584A (zh) * 2009-05-06 2012-07-04 贝尔韦什生物医学研究学会 用于治疗癌症的溶瘤腺病毒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US7608681B2 (en) * 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
CN101437538A (zh) 2006-04-28 2009-05-20 宾夕法尼亚州立大学托管会 修饰的腺病毒六邻体蛋白和其应用
EP2558481B1 (en) 2010-04-14 2017-12-20 Mogam Biotechnology Research Institute Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439055A (zh) * 2000-05-26 2003-08-27 住友制药株式会社 具有副作用降低的特性的新型重组腺病毒载体
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
CN101802013A (zh) * 2007-07-16 2010-08-11 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
CN101781636A (zh) * 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
CN102548584A (zh) * 2009-05-06 2012-07-04 贝尔韦什生物医学研究学会 用于治疗癌症的溶瘤腺病毒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
hexon [Human adenovirus 5],GenBank: AAO24099.1;Na et al.;《Genbank》;20030120;第1页 *
hexon [Human adenovirus 5],GenBank:BAG48782.1;Ishiko et al.;《Genbank》;20080614;第1页 *
Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation;Hongju Wu et al.;《Journal of Virology》;20050331;第79卷(第6期);第3382-3390页 *

Also Published As

Publication number Publication date
JP2017514483A (ja) 2017-06-08
KR20160145825A (ko) 2016-12-20
CA2946650A1 (en) 2015-11-05
EP2940128A1 (en) 2015-11-04
BR112016025297A2 (pt) 2017-10-17
US20200181208A1 (en) 2020-06-11
WO2015166082A1 (en) 2015-11-05
RU2016146664A (ru) 2018-05-30
US20230331786A1 (en) 2023-10-19
CA2946650C (en) 2023-07-11
BR112016025297B1 (pt) 2022-08-30
US10604549B2 (en) 2020-03-31
AU2015254535B2 (en) 2020-08-13
AU2015254535A1 (en) 2016-12-01
US11578104B2 (en) 2023-02-14
KR102628234B1 (ko) 2024-01-22
RU2711371C2 (ru) 2020-01-16
IL248590B (en) 2021-01-31
JP6639412B2 (ja) 2020-02-05
EP3137599A1 (en) 2017-03-08
MX2016014187A (es) 2017-05-03
IL248590A0 (en) 2016-12-29
RU2016146664A3 (enExample) 2018-06-28
MX381286B (es) 2025-03-12
CN106471125A (zh) 2017-03-01
US20170051022A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
US20230331786A1 (en) Adenovirus comprising an albumin-binding moiety
RU2520823C2 (ru) Аденовирусные векторы и способы и применения, связанные с ними
AU2011306845B2 (en) Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
CN104263703B (zh) 用于治疗癌症的嵌合腺病毒
CA2640528C (en) Oncolytic adenoviruses for cancer treatment
JP2022023074A (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
KR20120049185A (ko) 암 치료용 암 용해성 아데노바이러스
US20080044386A1 (en) Protamine-Adenoviral Vector Complexes and Methods of Use
EP1196616B1 (en) Replication-competent anti-cancer vectors
FI119176B (fi) Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo
EP4148126A1 (en) Immunoevasive anti-tumor adenovirus
CA2517294A1 (en) Method of using adenoviral vectors with increased persistencein vivo
JP4327844B2 (ja) 改善された癌細胞特異性と活性を有する変形されたテロメア逆転写酵素のプロモーターおよびこれを含む組み換えベクター
JP7508109B2 (ja) ヒト３５型アデノウイルスを基盤とした腫瘍溶解性ウイルス
JP2025503516A (ja) 免疫回避性抗腫瘍アデノウイルス
FI124926B (fi) Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant